Global Bioenergies S.A.

As of December 31, 2024, Global Bioenergies S.A. has 18.13M shares outstanding.

These figures are as of December 31, 2024. The EV/Sales ratio of 2.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of December 31, 2024, Global Bioenergies S.A. maintains a current ratio of 1.47, meaning it holds 1.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 334.06, indicating elevated leverage, while an interest coverage ratio of -20.38 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended December 31, 2024. Return on assets (ROA) is negative at -42.01, reflecting losses generated across the asset base. Inventory turnover of 1.18 indicates how many times Global Bioenergies S.A. sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on December 24, 2025, Global Bioenergies S.A.'s stock has declined approximately 97.81% over the past 52 weeks. The 50-day moving average sits at 0.02, while the 200-day moving average is 0.32.

Over the twelve months ended December 31, 2024, Global Bioenergies S.A. posted a gross margin of -59.26, reflecting its pricing power and cost economics. The operating margin of -1,689.49 and net profit margin of -1,625.06 provide insight into operational efficiency.

Global Bioenergies S.A.'s most recent stock split took place on March 8, 2023 with a 200:203 split ratio.

As of December 31, 2024, Global Bioenergies S.A. has an Altman Z-Score of -2.57, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.